drugset / Trial / NCT05411718

A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome

NCT05411718

RandomizedParallel-groupTriple-blindPrevention

Summary

To learn about the effects of naproxen and aspirin on the normal colon in people with Lynch Syndrome.

Timeline

Start
2023-03-21
Primary completion
2026-11-30
Completion
2026-11-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aspirin Small molecule Oral
Subject Naproxen Small molecule Oral

Indications